FDA
label_change
· 2019-09-26
FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
Summary
FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) from AbbVie. The action updates the product labeling to reflect the approval.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for MAVYRET (GLECAPREVIR AND PIBRENTASVIR)